Investigating how ULK2 helps prevent muscle loss as we age
Role of ULK2 in selective protein degradation and protection against sarcopenia
['FUNDING_OTHER'] · UNIVERSITY OF IOWA · NIH-11170823
This study is looking at how a protein called ULK2 helps get rid of damaged proteins in muscles, which could lead to new ways to keep older adults strong and healthy as they age and fight off muscle loss.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF IOWA (nih funded) |
| Locations | 1 site (IOWA CITY, UNITED STATES) |
| Trial ID | NIH-11170823 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific protein, ULK2, in the process of selective protein degradation, which is crucial for maintaining muscle health in older adults. As people age, they often experience sarcopenia, a condition characterized by muscle atrophy and weakness, which can severely impact their independence and overall health. The study will explore how ULK2 interacts with other proteins to facilitate the removal of damaged proteins in muscle cells, potentially leading to new therapeutic strategies for sarcopenia. By examining the mechanisms of autophagy, the research aims to identify ways to enhance muscle function and combat age-related decline.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing muscle weakness or atrophy, particularly those over the age of 65.
Not a fit: Patients who are younger than 21 or do not have any signs of muscle atrophy or weakness may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help preserve muscle mass and strength in older adults, improving their quality of life.
How similar studies have performed: Previous research has shown promising results in targeting autophagy for muscle health, indicating that this approach may lead to significant advancements in treating sarcopenia.
Where this research is happening
IOWA CITY, UNITED STATES
- UNIVERSITY OF IOWA — IOWA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIRA, VITOR A — UNIVERSITY OF IOWA
- Study coordinator: LIRA, VITOR A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.